These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38082520)

  • 41. Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma.
    Vitale MG; Nasso C; Oltrecolli M; Baldessari C; Fanelli M; Dominici M; Sabbatini R
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1183-1192. PubMed ID: 34424125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An update on Merkel cell carcinoma.
    Sergi MC; Lauricella E; Porta C; Tucci M; Cives M
    Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188880. PubMed ID: 36914034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
    [No Abstract]   [Full Text] [Related]  

  • 44. Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials.
    Zhuang TZ; Case K; Olsen TA; Brown JT; Carthon BC; Kucuk O; Goldman J; Harris W; Bilen MA; Nazha B
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
    [No Abstract]   [Full Text] [Related]  

  • 46. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
    Grisic AM; Xiong W; Tanneau L; Jönsson S; Friberg LE; Karlsson MO; Dai H; Zheng J; Girard P; Khandelwal A
    Clin Cancer Res; 2022 Apr; 28(7):1363-1371. PubMed ID: 34921021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US.
    Bharmal M; Kearney M; Zheng Y; Phatak H
    Clinicoecon Outcomes Res; 2019; 11():349-359. PubMed ID: 31190927
    [No Abstract]   [Full Text] [Related]  

  • 48. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Kim S; Wuthrick E; Blakaj D; Eroglu Z; Verschraegen C; Thapa R; Mills M; Dibs K; Liveringhouse C; Russell J; Caudell JJ; Tarhini A; Markowitz J; Kendra K; Wu R; Chen DT; Berglund A; Michael L; Aoki M; Wang MH; Hamaidi I; Cheng P; de la Iglesia J; Slebos RJ; Chung CH; Knepper TC; Moran-Segura CM; Nguyen JV; Perez BA; Rose T; Harrison L; Messina JL; Sondak VK; Tsai KY; Khushalani NI; Brohl AS
    Lancet; 2022 Sep; 400(10357):1008-1019. PubMed ID: 36108657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel.
    Averbuch I; Stoff R; Miodovnik M; Fennig S; Bar-Sela G; Yakobson A; Daliot J; Asher N; Fenig E
    Cancer Med; 2023 Jun; 12(11):12065-12070. PubMed ID: 37012213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
    Kaufman HL; Russell JS; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Milella M; Brownell I; Lewis KD; Lorch JH; von Heydebreck A; Hennessy M; Nghiem P
    J Immunother Cancer; 2018 Jan; 6(1):7. PubMed ID: 29347993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Die chronische venöse Insuffizienz - Eine Zusammenfassung der Pathophysiologie, Diagnostik und Therapie.
    Santler B; Goerge T
    J Dtsch Dermatol Ges; 2017 May; 15(5):538-557. PubMed ID: 28485867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Shindo T; Hashimoto K; Takahashi A; Miyamoto S; Kunishima Y; Sato S; Fukuta F; Hiyama Y; Takayanagi A; Kato R; Wanifuchi A; Ueki Y; Okada M; Adachi H; Kobayashi KO; Tanaka T; Masumori N;
    Anticancer Res; 2024 Mar; 44(3):1271-1279. PubMed ID: 38423657
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date.
    Sheng IY; Ornstein MC
    Cancer Manag Res; 2020; 12():4871-4881. PubMed ID: 32606975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.
    Torchio M; Cattaneo L; Milione M; Prinzi N; Corti F; Ungari M; Anichini A; Mortarini R; Occhini A; Bertino G; Maurichi A; Coppa J; Di Bartolomeo M; de Braud FG; Pusceddu S
    Front Oncol; 2021; 11():628324. PubMed ID: 34221958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
    Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
    Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Arzneimittelexantheme unter modernen zielgerichteten Therapien - Immuncheckpoint- und EGFR-Inhibitoren.
    Pospischil I; Hoetzenecker W
    J Dtsch Dermatol Ges; 2021 Nov; 19(11):1621-1645. PubMed ID: 34811897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
    Lavacchi D; Nobili S; Brugia M; Paderi A; Fancelli S; Caliman E; Vergoni F; Mini E
    BMC Cancer; 2018 Oct; 18(1):1024. PubMed ID: 30348121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
    Ugolini H; Bryan J; Hennessy M; Kaufman HL; D'Angelo S
    Clin J Oncol Nurs; 2019 Feb; 23(1):E1-E9. PubMed ID: 30682006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
    Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
    Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.